Probable interaction between warfarin and a toothache solution containing Piper longum L. leading to ischemic stroke: a case report.

J EthnopharmacolApr 29, 2026 (epub)
Case ReportInternal Medicine (General)Cardiology

Jing Huang, Chenchen Sun, Guodong Lou

✦ AI-curated · Sources linked

Case in brief

A patient with a mechanical heart valve on warfarin experienced fluctuations in their international normalized ratio (INR) and subsequently suffered an ischemic stroke. Investigation revealed a probable interaction between warfarin and a toothache solution containing Piper longum L., which contributed to the stroke. The case highlights the importance of monitoring potential drug interactions in patients on anticoagulation therapy.

Diagnostic / clinical pearl

Clinicians should be aware of the potential interaction between warfarin and herbal remedies, such as Piper longum, which can lead to significant adverse events like ischemic stroke.

Source

PubMed · PMID 42066825

Published in J Ethnopharmacol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Internal Medicine (General)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.